These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 34459036)

  • 1. Clinicopathological features of cutaneous reactions after mRNA-based COVID-19 vaccines.
    Tihy M; Menzinger S; André R; Laffitte E; Toutous-Trellu L; Kaya G
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2456-2461. PubMed ID: 34459036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.
    Català A; Muñoz-Santos C; Galván-Casas C; Roncero Riesco M; Revilla Nebreda D; Solá-Truyols A; Giavedoni P; Llamas-Velasco M; González-Cruz C; Cubiró X; Ruíz-Villaverde R; Gómez-Armayones S; Gil Mateo MP; Pesqué D; Marcantonio O; Fernández-Nieto D; Romaní J; Iglesias Pena N; Carnero Gonzalez L; Tercedor-Sanchez J; Carretero G; Masat-Ticó T; Rodríguez-Jiménez P; Gimenez-Arnau AM; Utrera-Busquets M; Vargas Laguna E; Angulo Menéndez AG; San Juan Lasser E; Iglesias-Sancho M; Alonso Naranjo L; Hiltun I; Cutillas Marco E; Polimon Olabarrieta I; Marinero Escobedo S; García-Navarro X; Calderón Gutiérrez MJ; Baeza-Hernández G; Bou Camps L; Toledo-Pastrana T; Guilabert A
    Br J Dermatol; 2022 Jan; 186(1):142-152. PubMed ID: 34254291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan.
    Kitagawa H; Kaiki Y; Sugiyama A; Nagashima S; Kurisu A; Nomura T; Omori K; Akita T; Shigemoto N; Tanaka J; Ohge H
    J Infect Chemother; 2022 Apr; 28(4):576-581. PubMed ID: 35058126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database.
    Falotico JM; Desai AD; Shah A; Ricardo JW; Lipner SR
    Am J Clin Dermatol; 2022 Sep; 23(5):729-737. PubMed ID: 35931925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system.
    Chapin-Bardales J; Myers T; Gee J; Shay DK; Marquez P; Baggs J; Zhang B; Licata C; Shimabukuro TT
    Vaccine; 2021 Nov; 39(48):7066-7073. PubMed ID: 34763946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: An observational study.
    Grieco T; Maddalena P; Sernicola A; Muharremi R; Basili S; Alvaro D; Cangemi R; Rossi A; Pellacani G
    Dermatol Ther; 2021 Nov; 34(6):e15153. PubMed ID: 34622531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination.
    Larson V; Seidenberg R; Caplan A; Brinster NK; Meehan SA; Kim RH
    J Cutan Pathol; 2022 Jan; 49(1):34-41. PubMed ID: 34292611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study.
    Cebeci Kahraman F; Savaş Erdoğan S; Aktaş ND; Albayrak H; Türkmen D; Borlu M; Arıca DA; Demirbaş A; Akbayrak A; Polat Ekinci A; Gökçek GE; Çelik HA; Taşolar MK; An İ; Temiz SA; Hazinedar E; Ayhan E; Hızlı P; Solak EÖ; Kılıç A; Yılmaz E
    J Cosmet Dermatol; 2022 Sep; 21(9):3692-3703. PubMed ID: 35780311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy.
    Inoue S; Igarashi A; Morikane K; Hachiya O; Watanabe M; Kakehata S; Sato S; Ueno Y
    Respir Investig; 2022 Mar; 60(2):248-255. PubMed ID: 34920980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort.
    Nguyen VG; Yavlinsky A; Beale S; Hoskins S; Byrne TE; Lampos V; Braithwaite I; Fong WLE; Fragaszy E; Geismar C; Kovar J; Navaratnam AMD; Patel P; Shrotri M; Weber S; Hayward AC; Aldridge RW
    Int J Epidemiol; 2023 Apr; 52(2):342-354. PubMed ID: 36655537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine.
    López-Valle A; Falkenhain-López D; Arranz CR
    Int J Dermatol; 2021 Jul; 60(7):891-892. PubMed ID: 33855706
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
    Matsumura A; Katsuki K; Akimoto M; Sakuma T; Nakajima Y; Miyazaki T; Fujisawa S; Nakajima H
    Rinsho Ketsueki; 2021; 62(11):1639-1642. PubMed ID: 34866090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults.
    Harris DA; Hayes KN; Zullo AR; Mor V; Chachlani P; Deng Y; McCarthy EP; Djibo DA; McMahill-Walraven CN; Gravenstein S
    JAMA Netw Open; 2023 Aug; 6(8):e2326852. PubMed ID: 37531110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.
    McMahon DE; Amerson E; Rosenbach M; Lipoff JB; Moustafa D; Tyagi A; Desai SR; French LE; Lim HW; Thiers BH; Hruza GJ; Blumenthal KG; Fox LP; Freeman EE
    J Am Acad Dermatol; 2021 Jul; 85(1):46-55. PubMed ID: 33838206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
    Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
    Front Immunol; 2022; 13():956825. PubMed ID: 36177033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.
    Sibbel S; McKeon K; Luo J; Wendt K; Walker AG; Kelley T; Lazar R; Zywno ML; Connaire JJ; Tentori F; Young A; Brunelli SM
    J Am Soc Nephrol; 2022 Jan; 33(1):49-57. PubMed ID: 34789546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.